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Abstract  
Objectives: To investigate unwarranted variation in ventilation tube (VT) insertions for 
otitis media with effusion (OME) in children in England. This procedure is known to be 
µRYHUXVHG¶IURPDXGLWVRIFDUHSrovided, as only one in three VT insertions conform to the 
appropriateness criteria by the National Institute for Health and Clinical Excellence 
(NICE); but audits cannot identify WKHVFDOHRIµXQGHUXVH¶: i.e. patients who would benefit 
but are not treated.  
Methods: 7R H[SORUH ERWK µXQGHUXVH¶ DQG µRYHUXVH¶ of VTs for OME we developed an 
epidemiological model based on: definitions of children with OME expected to benefit 
from VTs according to NICE guidance; epidemiological and clinical information from a 
systematic review; and expert judgement. A range of estimates was derived using Monte 
Carlo simulation and compared with the number of VTs actually provided in the NHS in 
2010.  
Results: About 32,200 children in England would be expected to benefit from VTs for 
OME per year (between 20,411 and 45,231 with 90% certainty). The observed number of 
VTs for OME-associated diagnoses however was 16,824.  
Conclusions: The expected population capacity to benefit from VTs for OME based on 
NICE guidance appeared to exceed, by far, the number of VTs actually provided in the 
NHS. So, while there is NQRZQµRYHUXVH¶WKHUHalso may EHVXEVWDQWLDOµXQGHUXVH¶ of VTs 
for OME if NICE criteria were applied. Future investigations of unwarranted variation 
should therefore not only focus on patients who are treated, but consider potential to 
benefit at the population level. 
Introduction  
Systems of healthcare in countries that are under severe fiscal pressures1 seek to do more 
for less: to increase the benefits from healthcare and reduce its costs. There is evidence of 
large and persistent variations in medical practice across small areas, which have been 
documented in various countries.2 This evidence is generally seen as an indication of  
µRYHUXVH¶LHZKHUHUHGXFWLRQVLQUDWHVRIWUHDWPHQWFRXOGUHOHDVHUHVRXUFHVZLWKJDLQVLQ
health.3 In England, commissioners are allocated budgets for their populations and have 
to develop policies for services for which they are and are not prepared to pay. One such 
policy seeks to reduce unwarranted variation by restricting access to procedures listed as 
EHLQJRI µORZFOLQLFDOYDOXH¶.4 However, due to the lack of an objective reference point 
agaLQVWZKLFKWRHYDOXDWHµRYHUXVH¶LQHIIHFWLYHFDUHWKDWLVPRUHOLNHO\WRKDUPWKDQKHOS
the patient5RUµXQGHUXVH¶WKHIDLOXUHWRSURYLGHVHUYLFHVIURPZKLFKWKHSDWLHQWZRXOG
likely benefit5), information on variations remains essentially ambiguous.6 The purpose of 
this article is to inveVWLJDWHXQZDUUDQWHGYDULDWLRQVE\PRGHOOLQJWKHVFDOHRIµXQGHUXVH¶
RU µRYHUXVH¶ RI ventilation tubes (VTs; grommets) for children with otitis media with 
effusion (OME) in England.  
VT insertions are a classic case of high geographic variation. Variations in England have 
been documented since the 1980s7 and have persisted: in 2010/11 there was about eight-
fold variation across 151 commissioners (with a mean population of about 300,000).8 VTs 
have been listed by commissioners DV D µORZYDOXH¶SURFHGXUH,4 which seeks to restrict 
referrals by general practitioners (GPs). Despite that, VT insertions remain one of the 
most frequent surgical interventions in children: with over 32,000 insertions in 2010/11, 
of which 23,500 were among children younger than 14 years.9 Clinical audits in the US10 
and the UK,11 using different criteria of appropriateness, found that only one in three VT 
LQVHUWLRQV ZHUH DSSURSULDWH VXJJHVWLQJ VXEVWDQWLDO µRYHUXVH¶. However, audits of care 
GHOLYHUHG FDQQRW DGGUHVV WKH VFDOH RI µXQGHUXVH¶ RI VTs for OME. We therefore 
developed an epidemiological model to estimate the number of children with capacity to 
benefit from VTs for OME, if NICE guidance12 were being followed, and compared this 
with the number of VTs actually provided in England.  
Recommended clinical pathway   
OME is defined as an effusion in the middle ear cleft, in the absence of signs of acute 
inflammation. It may cause conductive hearing loss, which, if persistent, can affect 
speech and language development, educational performance and behaviour.13 By the age 
of four years, about 80% of children have had episodes of OME.14 As OME is transitory 
for most children, the NICE clinical pathway (Figure 1) recommends an initial period of 
active observation over three months and repeat audiological testing at the end of this 
period. At that stage, it is recommended that VTs are offered for children younger than 12 
\HDUV ZKR PHHW WKUHH µFRUH¶ FULWHULD  ELODWHUDO 20( ZLWK  D KHDULQJ OHYHO LQ WKH
better hearing ear of 25 to 30 dBHL or higher that (3) is documented over a period of 
three months. The crucial point is that NICE guidance does not define VTs as an 
intrinsically µORZ YDOXH¶ procedure, but recognises their value in relation to a set of 
evidence-based criteria. In exceptional cases, VTs may also be offered if clinicians judge 
the impact of OME-related heDULQJLPSDLUPHQWRQWKHFKLOG¶VGHYHORSPHQWZHOO-being or 
social functioning to be substantial.12  
Methods  
Based on the NICE criteria, our epidemiological model to estimate population capacity to 
benefit from VTs for OME is formulated below. The modelling assumptions are 
summarised in Table 1. The parameters, their definition and estimation are given in Table 
2. 
1) Incidence: The number of new cases of OME in any given year, N(OME), is 
determined by the annual age-specific cumulative incidence (risk) Ij of OME multiplied 
by the susceptible population in a given age group Sj, summed over all eligible age groups 
j. The subgroup of cases with bilateral OME and a hearing level at NICE threshold level 
is expressed by 
 
2) Disease process: We model the probability of OME persisting at time t from the onset 
of OME as an exponential process (adapted from15) of the form 
P (OME | t) =     
3) Capacity to benefit from VTs for OME: As OME is transitory, the population with 
capacity to benefit will diminish as time passes since the onset of OME. Population 
capacity to benefit from VTs for OME is estimated as 
PCB (t) = P (OME | t) * N (OME) 
> Figure 1: NICE clinical pathway < 
> Table 1: Modelling assumptions <  
> Table 2: Model parameters <  
Data sources and extraction 
To estimate parameter values, we carried out a systematic literature review according to 
PRISMA guidelines16 (see Appendix A for details of the search strategy and data 
extraction, Appendix B for the rationale for the study inclusion criteria).  
Setting and population 
The setting is the National Health Service (NHS) in England. The population includes 
children younger than 12 years covered by NICE guidance. However, as we were unable 
to find incidence studies that met our inclusion criteria for the age groups 0, 1, 4 and 9 to 
12 years, we focused the analysis on children aged 2 to 8 years (extrapolating the 
incidence for 4-year olds from 3-year olds) which is the age group with the majority of 
VT insertions (0 to 12 years: 19,805; 2 to 8 years: 16,824 procedures with OME-
associated diagnoses in 2010/119). To estimate the susceptible population, the total 
population of children has been corrected for an estimate of OME prevalence (Appendix 
C:HIRFXVHGRQFKLOGUHQPHHWLQJWKHWKUHH1,&(µFRUH¶FULWHULDIRUVT insertion. The 
number of exceptional cases, which are identified through clinical judgement, was not 
modelled. This means that estimates from our epidemiological model are probably 
conservative and underestimate the number of children with capacity to benefit from VTs. 
Model validation 
All modelling assumptions were iteratively refined in consultation with the Project 
Steering Group. During an expert workshop in September 2012, ten participants with 
complementary expertise in audiology, ENT, general practice and epidemiology were 
LQYLWHG WR FRQGXFW D VWUXFWXUHG µZDONWKURXJK¶ WR H[DPLQH WKH PRGHO¶V RYHUDOO VWUXFWXUH
and individual components. The group judged the model to be a fair representation of the 
NICE care pathway and of the disease process governing OME given the existing 
evidence base. 
Sensitivity analysis 
Data retrieved from the literature raised the issue of potential for bias in terms of internal 
validity (the extent to which the design of original studies ensured accurate measurement 
of the parameters of interest) and external validity (the extent to which studies conducted 
e.g. two decades ago in a different setting were applicable to the present UK context). 
While we recognise the relevance of the literature-based data, we felt the different sources 
of uncertainty in the evidence would merit supplementing this with expert judgement. We 
followed a structured approach to expert elicitation.17 We provided the panel of experts 
with the literature-based estimates, encouraged discussion and elicited fractiles of 
subjective probability distributions. We then used these estimates in a Monte Carlo 
simulation performed in @RISK 5.0 to gain an insight into the impact of the combined 
uncertainty in parameter estimates on the modelling results.18 
Results  
Figure 2 illustrates the combined uncertainty in the expected incidence of bilateral OME 
with a hearing level of +25 dB. Based on 10,000 iterations of the model and given the set 
of input distributions, the resulting distribution of the expected incidence ranges between 
63,800 and 143,600 cases per year in England with 90% certainty (mean estimate: 102,083 
cases). These results from the Monte Carlo simulation are used to model the expected 
number of children with capacity to benefit from VTs for OME as the total waiting time 
from the onset of OME is varied over a range.  
Since OME is transitory, the expected population capacity to benefit from VTs for OME 
depends on the total waiting time from the onset of OME to the point where treatment is 
considered (Figure 3). NICE guidance recommends a three-month period of active 
observation following the first formal diagnosis. Thus, if we were to assume the first 
outpatient appointment took place instantaneously after the onset of OME, then the mean 
estimate of children for whom VTs would be clinically indicated would be approximately 
51,000 (at t=3 months; between 32,400 and 71,800 with 90% certainty). There is currently 
no national guidance on the recommended waiting time from the onset of OME until the 
first outpatient appointment (waiting time intervals t1 and t2 in Figure 1). Since our model 
aims to provide a benchmark of expected care, rather than a reflection of actual practice, 
our assumptions about the length of these intervals (Table 2) represent clinically µideal¶ 
circumstances based on expert group consensus. Assuming a one-month buffer period 
before parents become concerned about the symptoms of OME and visit a GP and another 
month before children have their first outpatient appointment, we would expect 
approximately 32,200 children to benefit from VTs for OME (at t=5 months; 90% 
certainty LQWHUYDO WR7KLVFRQWUDVWVZLWKDQµREVHUYHG¶QXPEHURI
VTs that were actually provided for OME-associated diagnosis codes in the age group of 2 
to 8 years in 2010/11 in England. As can be seen in Table 3, even if we were to assume 
coding inaccuracies in VTs coded with OME-associated diagnoses, the conclusions would 
be unaffected. 
> Figure 2: Monte Carlo simulation < 
> Figure 3: Capacity to benefit from VTs for OME < 
> Table 3: Observed number of VT insertions in England, 2010/11 < 
 
 
Discussion  
This study shows that the expected capacity to benefit from VTs for OME among children 
in England, according to NICE guidance, exceeds the number of VTs that were actually 
provided in the NHS. 2XU PRGHO KHQFH UHYHDOV WKH SRVVLELOLW\ RI µXQGHUXVH¶ RI VTs for 
OME at the aggregate national level. However, the findings also need to be interpreted in 
the light of the roughly eight-fold variation in treatment rates across PCTs in England,8 
which suggests that µRYHUXVH¶PLJKWVWLOORFFXULQsome regions.  
Strengths and weaknesses of the study  
The model draws on evidence-based clinical guidance to obtain an indicative estimate of 
the VFDOHRISRWHQWLDOµXQGHUXVH¶RUµRYHUXVH¶RIVTs in a given population. This estimate 
GRHV QRW UHSUHVHQW WKH µULJKW WUHDWPHQW UDWH¶ ZKLFK ZRXOG DOVR GHSHQG RQ LQIRUPHG
patient choice. It attempts to approximate a level of treatment that the NHS would be 
expected to offer to patients, if NICE criteria were accepted as a valid basis for identifying 
patients with capacity to benefit from VTs. We recognise that NICE criteria can only be 
approximate SUHGLFWRUV RI µEHQHILW¶ from VTs for hearing outcomes, especially for cases 
located just above or below the +25dBHL threshold, with even more uncertainty over the 
impact of VTs on childhood development and WKH FKLOG¶V Quality of Life. Thus, from a 
normative standpoint, our model can only give an approximate estimate of how many VTs 
µVKRXOG¶EHRIIHUHG, which may change once better predictors of benefit become available.  
The model uses best available evidence identified through a systematic review. The 
shortage of high-quality studies meeting our inclusion criteria did not allow for a meta-
analysis, and we have demonstrated the consequent uncertainty in our parameter estimates 
and their combined impact on the modelling results by Monte Carlo simulation. The 
observed number of VTs provided covers patients treated in the NHS; unfortunately we 
were unable to obtain estimates of the scale of private practice in England. However, total 
private sector expenditure on healthcare in the UK (2011) is 17.2%,19 which would not 
substantially affect the conclusions of our study.  
Findings in relation to studies of utilisation 
Our study using a population model complements utilisation-based studies of treatment 
appropriateness. A recent multi-centre study in England found that only 32.2% of VTs 
inserted complied ZLWKWKHWKUHHµFRUH¶1,&(FULWHULDZKLOHRIVTs were provided on 
WKHEDVLVRI µH[FHSWLRQDO FLUFXPVWDQFHV¶.11 Although NICE guidelines explicitly encourage 
the provision of VTVDOVREH\RQG WKH WKUHH µFRUH¶FULWHULD LIFOLQLFLDQV MXGJH WKH LPSDFWRI
OME on the FKLOG¶V GHYHORSPHQW DQG VRFLDO IXQFWLRQLQJ WR EH VXEVWDQWLDO,12 the apparent 
UHIUDPLQJRIµH[FHSWLRQV¶XQGHUFOLQLFDOJXLGDQFHDVWKHµUXOH¶LQFOLQLFDOSUDFWLFHGRHVUDLVH
questions over treatment appropriateness. This study adds to these findings by illustrating 
WKDW ZKLOH WKHUH PD\ EH GHYLDWLRQ IURP 1,&( µFRUH¶ criteria, which could either reflect 
patient-RULHQWHG WUHDWPHQW RU µRYHUXVH¶ RI VTV µXQPHW FOLQLFDO QHHG¶ DFFRUGLQJ WR WKHVH
µFRUH¶FULWHULDPD\EHSUHVHQWVLPXOWDQHRXsly. 
Policy implications  
An increasingly common policy among healthcare commissioners in England4 is to label 
VTs per se DVµRYHUXVHG¶DQGµORZYDOXH¶and hence restrict access to the procedure. Our 
findings highlight the possibility of VXEVWDQWLDOµXQGHUXVH¶ among children in England for 
whom VTs are deemed beneficial and thus call for a more nuanced policy response. 
Because there is no evidence of a systematic relationship between high rates of utilisation 
and high rates of inappropriateness,20 we need a policy that tackles overuse by clinical 
audit of treatment, and ensures access to effective care for children suffering from 
persistent bilateral OME with a degree of hearing loss that is disabling and may affect 
their health and development. This policy would use the ideas of epidemiologic 
surveillance of medical care21 to enlarge the framing of clinical appropriateness from 
audits of services delivered to population capacity to benefit. Understanding the number 
of people who might be expected to benefit, given local population characteristics and 
clinical guidance, has relevance also for other high-volume services such as cataract 
surgery, joint arthroplasty or spinal procedures: it could help widen clinical concerns 
from individual patients towards the entire population who could (not) benefit and should 
hence (not) be offered a procedure. This policy would require investments in: (1) 
recommended intervention criteria that are more directly related to patient benefit, based 
on evidence from everyday practice (high-quality clinical databases rather than RCTs) on 
the real-world impacts of surgery on health outcomes compared to a control group; and 
(2) good information on disease epidemiology. 
Implications for research and quality improvement 
To explain tKHGLVFUHSDQF\EHWZHHQµREVHUYHG¶VT SURYLVLRQVDQGWKHµH[SHFWHG¶QXPEHU
of VTs offered, a multi-faceted qualitative and quantitative approach involving 
commissioners, professionals and families is needed to identify barriers along the whole 
pathway and then design interventions for improvement. As parents, teachers and 
nurseries may fail to recognise hearing loss associated with OME,22 it is possible that 
many patients do not present to primary care in the first place. GPs, school nurses and 
health visitors need the knowledge and capacity to identify patients with suspected OME 
and ensure timely referral and diagnosis according to NICE criteria; in a recent UK-based 
study, participating GPs correctly identified OME only in 53% of cases, which is not 
much higher than chance.23 Since VTV IHDWXUHZLGHO\DVD µORZYDOXH¶SURFHGXUH,4 GPs 
might also tend to withhold referrals even for patients for whom VTs could be a clinically 
and cost-effective option. 'HOD\V LQ FDUH DQG D ORQJ KLVWRU\ RI µZDWFKIXO ZDLWLQJ¶ LQ
community services may thus, in practice, exceed the two-month interval from the onset 
of OME to formal diagnosis which we assumed as a clinicall\µLGHDO¶EHQFKPDUN in our 
model. To overcome fragmentation, GPs, audiologists and ENT specialists need to work 
together to ensure early recognition and referral of children with capacity to benefit from 
treatment. Patients and carers deliberately choosing non-surgical treatment alternatives, 
such as hearing aids or medical management, may also in part explain the apparent 
GLVFUHSDQF\EHWZHHQµH[SHFWHG¶DQGµREVHUYHG¶. However, many patients and carers may 
not be given the opportunity to discuss and understand their options for treatment, 
resulting in uninformed use of other care. Future research might therefore also examine 
regional variations in patient preferences and approaches to shared decision-making24 and 
how these add to, or interact with, differences in local commissioning criteria and socio-
economic inequalities.  
Conclusions 
This study has highlighted the case of VTs for OME which, although known to be 
µRYHUXVHG¶ EDVHG RQ DXGLWV RI FDUe provided, simultaneously seem to exhibit substantial 
µXQGHUXVH¶DWDSRSXODWLRQ OHYHO LQ(QJODQGEDVHGRQ1,&(JXLGDQFH%HFDXVHµRYHUXVH¶
DQGµXQGHUXVH¶PD\FR-exist as sources of unwarranted variation, clinicians and managers 
should examine if all children who would be expected to benefit from VTs for OME also 
have access to the procedure. The study is of one condition in England but raises an 
important general issue over using studies of medical practice variations to inform policies 
WRUHGXFHµRYHUXVH¶DQGWKXVUelease resources to meet rising demand in times of austerity. 
To maximise benefits for patients within resource constraints, policies where medical 
SUDFWLFHYDULHVRXJKWWRWDFNOHµRYHUXVH¶E\DXGLWLQJFDUHWKDWLVSURYLGHGDQGµXQGHUXVH¶
by assessing capacity to benefit in populations.  
References for the text 
1. Mladovsky P, Srivastava D, Cylus J, et al. Health policy responses to the financial 
crisis in Europe. Copenhagen: World Health Organization, 2012. 
2. Corallo AN, Croxford R, Goodman DC, Bryan EL, Srivastava D and Stukel TA. A 
systematic review of medical practice variation in OECD countries. Health Policy. 2013. 
3. Ham C. Doctors must lead efforts to reduce waste and variation in practice. BMJ. 
2013; 346: f3668. 
4. Audit Commission. Reducing spending on low clinical value treatments. London: 
Audit Commission, 2011. 
5. Institute of Medicine. Crossing the Quality Chasm. Washington: National 
Academy Press, 2001. 
6. Evans R. The Dog in the Night-Time. In: Andersen TV and Mooney G, (eds.). The 
Challenges of Medical Practice Variation London: MacMillan, 1990, pp. 117-52. 
7. Black N. Geographical variations in use of surgery for glue ear. J R Soc Med. 1985; 
78: 641-8. 
8. NHS Right Care. NHS Atlas of Variation in Healthcare for Children and Young 
People, 2012; p.55. Available at: http://www.rightcare.nhs.uk/index.php/atlas/children-
and-young-adults/2012. 
9. NHS Information Centre. Main procedures and interventions: 4 character. 
Hospital Episode Statistics for England. Inpatient statistics, 2010-11. Procedure D15.1 
Myringotomy with insertion of ventilation tube through tympanic membrane, 
www.hesonline.nhs.uk (accessed 10 January 2013). 2011. 
10. Keyhani S, Kleinman LC, Rothschild M, Bernstein JM, Anderson R and Chassin 
M. Overuse of tympanostomy tubes in New York metropolitan area: evidence from five 
hospital cohort. BMJ. 2008; 337: a1607. 
11. Daniel M, Kamani T, El-Shunnar S, et al. National Institute for Clinical Excellence 
guidelines on the surgical management of otitis media with effusion: are they being 
followed and have they changed practice? Int J Pediatr Otorhinolaryngol. 2013; 77: 54-8. 
12. NICE Guidance. Surgical management of children with otitis media with effusion 
(OME) Clinical guidelines, CG60. 2008. 
13. Simpson SA, Thomas CL, van der Linden MK, Macmillan H, van der Wouden JC 
and Butler C. Identification of children in the first four years of life for early treatment for 
otitis media with effusion. Cochrane Database Syst Rev. 2007: CD004163. 
14. Zielhuis GA, Rach GH and Van den Broek P. The occurrence of otitis media with 
effusion in Dutch pre-school children. Clin Otolaryngol Allied Sci. 1990; 15: 147-53. 
15. Zielhuis GA, Rach GH and van den Broek P. The natural course of otitis media 
with effusion in preschool children. Eur Arch Otorhinolaryngol. 1990; 247: 215-21. 
16. Moher D, Liberati A, Tetzlaff J and Altman DG. Preferred reporting items for 
systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339: b2535. 
17. O'Hagan A, Buck C, Daneshkhah A, et al. Uncertain Judgements. Eliciting 
Experts' Probabilities. Chichester, England: Wiley, 2006. 
18. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ and Paltiel AD. 
Model Parameter Estimation and Uncertainty Analysis: A Report of the ISPOR-SMDM 
Modeling Good Research Practices Task Force Working Group-6. Med Decis Making. 
2012; 32: 722-32. 
19. ONS. Expenditure on healthcare in the UK: 2011, www.ons.gov.uk (2013, 
accessed 12 August 2013). 
20. Keyhani S, Falk R, Bishop T, Howell E and Korenstein D. The relationship 
between geographic variations and overuse of healthcare services: a systematic review. 
Med Care. 2012; 50: 257-61. 
21. Caper P. The epidemiologic surveillance of medical care. Am J Public Health. 
1987; 77: 669-70. 
22. Rosenfeld RM, Goldsmith AJ and Madell JR. How accurate is parent rating of 
hearing for children with otitis media? Archives of Otolaryngology-Head & Neck Surgery. 
1998; 124: 989-92. 
23. Buchanan CM and Pothier DD. Recognition of paediatric otopathology by General 
Practitioners. Int J Pediatr Otorhinolaryngol. 2008; 72: 669-73. 
24. Elwyn G, Laitner S, Coulter A, Walker E, Watson P and Thomson R. 
Implementing shared decision making in the NHS. BMJ. 2010; 341: c5146. 
 
Acknowledgements: We would like to especially thank Martin Birchall for his enthusiasm 
and support for the project; Simon Swift and Adam Ceney for facilitating access to 
Hospital Episode Statistics data; members of the steering group including Bengi Beyzade, 
General Practitioner in Islington; Ian Colvin, General Practitioner at Elizabeth Avenue 
Group Practice, Islington; Kelvin Kwa, ENT Clinical Fellow at the UCL Ear Institute; 
James Mountford, Director of Clinical Quality at UCLPartners; and the expert panel who 
generously gave their time, insight and judgement to discuss the model: Martin Birchall, 
Professor of Laryngology at RNTNE; George Browning, Professor of Otorhinolaryngology 
at the MRC Institute of Hearing Research in Glasgow; Thembela Guzula, Senior 
Audiologist at Barts Health; Julie Hare, Consultant Speech and Language Therapist at 
RNTNE; Martin Marshall, Professor of Healthcare Improvement at UCL; Seema Patel, 
Lead Audiologist at Barts Health; and one paediatric ENT consultant who wished to 
remain anonymous. The conclusions reached are those of the authors. The authors alone 
are responsible for any mistakes.  
Conflicting interests: ML was funded by the National Collaborating Centre for Women 
DQG&KLOGUHQ¶V+HDOWKIRUKHUWLPHDVDFOLQLFDOGLUHFWRUWRVXSSRUWOHDGLQJWKHGHYHORSPHQW
of the NICE OME guideline, is co-author on the ENT-UK commissioning guidance for 
OME, and co-applicant on a study recently submitted for funding to the HTA on OME. 
Funding: This work was supported by the Health Foundation [grant number 6179]. 
17 
 
Table 1. Modelling assumptions  
a
 References are given in Appendix D. 
 Assumption Comment 
1 Exponential disease 
process  
For the population level an exponential and rate-constant recovery process is applied based on 
Zielhuis et al.1 The authors found a good fit (r2 = 0.98) between the exponential model  
estimated with Kaplan-Meier technique and the empirical data from a prospective cohort study 
(n=816 children with valid measurements). For a discussion of the epidemiological models for 
representing the natural course of OME see2 However, this may mask the few children suffering 
from highly persistent OME. At the individual level, OME may also be more episodic. 
2 Stationary 
population   
Assumes a stable age distribution within each age group and year (based on mid-year 
population estimates). 
3 t 
 
Total waiting time t represents a parameter that reflects demand- and supply-side aspects of 
patient utilisation behaviour, access and referral policies and the organisation of care delivery.  
Is varied over a range to account for uncertainy in three distinct sub-intervals: 
x t1,  time to presentation in primary care: Seeks to account for the time lag for detecting 
hearing loss associated with OME. As OME is an often asymptomatic or µVLOHQW¶
condition, conductive hearing loss is likely to be noted by parents, teachers or carers 
only after some time (if at all).  
x t2, time from presentation in primary care to diagnosis in specialist care:   According 
to the NHS Constitution, patients have a right to be seen by a consultant within 
maximum 18 weeks after referral.3 This is a political rather than clinical standard. It 
also refers to maximum not to optimum waiting times. National HES data confirms a 
median waiting time of 7.3 weeks (51 days) for grommets4 from the decision to admit 
to actual admission (excluding days of deferment and suspension).   
x t3, time from diagnosis to confirmation: supposed to be 3 months according to NICE 
guidance. 
4 Incidence is 
represented as a 
function of age 
Age-based incidence rates are used as the association of OME with age is well-established and 
most reliably documented.5  
5 Incidence rates are 
at a population 
level and include 
both first and 
recurrent cases 
About 50% of children recovering from OME experience a further episode of OME 6; 1. 
However, due to the often asymptomatic character of OME, even robust incidence studies 
cannot rule out the possibility that a child has previously suffered from OME. Modelling history 
of OME could thus lead to an overestimation of cases. Therefore incidence rates used in the 
model do not differentiate between first-time and recurrent cases and are assumed to include 
both. 
6 Incident cases Potential underestimation of transient cases occuring and recovering between the screening 
intervals of 3 months7 or 4 months.8 However, OME is considered a disease occuring only after 
several weeks of middle ear pathology.2 
7 Seasonal variation 
in incidence is 
averaged out over 
one year. 
The incidence of OME is known to be higher in winter; however, the incidence data used in the 
model and the model output represent an annual average. 
8 Fixed proportion of 
bilateral OME. 
Reflects the nature of the data that  has been collected at (discrete) screening time points; 
although  at individual level, children may switch between unilateral and bilateral states . 
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Table 2. Model parameters 
Parameter Definition Base value used 
in model 
Referencesa Distribution for sensitivity 
analysis 
Lower quartile; 
upper quartile10c 
Sj 
Number of susceptible children in age group j at risk of 
developing OME in a given year (reference year 2010). See Appendix B 
1
 - - 
Ij Age-specific cumulative incidence (risk) of transiting 
to the OME state over a period of one year by year of 
age. Diagnosis based on type B tympanogram by the 
Jerger classification and otoscopy. 
    
2 0.350 2 ȕ 0.280;0.420 
3 0.160 2 ȕ 0.128;0.192 
4 0.160 10a ȕ 0.128;0.192 
5 0.278 3 ȕ 0.222;0.334 
6 0.151 3 ȕ 0.121;0.181 
7 0.111 3 ȕ 0.088;0.133 
8 0.065 3 ȕ 0.056;0.084 
P (Bilateral OME | OME) Conditional probability of bilateral OME given a diagnosis of OME. 
0.4 3 ȕ 0.38;0.41 
P (HL | Bilateral OME) Conditional probability of a hearing level of 
+25dBgiven a diagnosis of bilateral OME. 
0.35 
 
4
 ȕ 0.3;0.4 
m 0HGLDQWLPHWRUHFRYHU\µKDOIOLIH¶RI20( 
3 months (three-
month recovery 
rate of 0.5) 
5-8
 Used as deterministic value in the model as found to be 
consistent across different settings and time periods by 
various studies. 
t Total waiting time t from OME onset  t1 + t2 + t3  See Table 1 Varied over a range from 0 to 25 weeks 
 
t1 Time from OME onset to presentation in primary care 1 month 10b   
t2 
Time from presentation in primary care to formal 
diagnosis  
1 month 10b   
t3 
Time from formal diagnosis to offer of treatment 
µDFWLYHREVHUYDWLRQ¶ RUµZDWFKIXOZDLWLQJ¶) 
3 months 9   
a
 References are given in Appendix D.
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Table 3. Observed VT insertions in England, 2010/11  
Observed VT insertions Count 
Total admissions 32,716 
Day case 29,566 
Age 0-14 23,459 
Age 0-12, OME-associated diagnosis codes (2010/11)* 19,805 
Age 2-8, OME-associated diagnosis codes (2010/11)* 16,824 
 
Source: NHS Information Centre. Main procedures and interventions: 4 character. Hospital Episode Statistics 
for England. Inpatient statistics, 2010-11.  
* Procedure code D15.1 Myringotomy with insertion of ventilation tube through tympanic membrane for 
DIAG1=H652: Chronic serous otitis media or H653: Chronic mucoid otitis media or H654: Other chronic 
nonsuppurative otitis media or H659: Nonsuppurative otitis media, unspecified. Both as primary and 
secondary procedure (e.g. besides adenoidectomy); including both elective and emergency admissions, in- 
and outpatient cases 
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Figure 1. Conceptual model: NICE pathway of care 
 
Explanation:  
(1) The model starts with a population of children at risk of developing OME.  
(2) Of these children, some will develop bilateral OME with a hearing level of +25 dBHL.  
7KH UHFRYHU\ UDWH GHWHUPLQHV WKHSURSRUWLRQRI FKLOGUHQ UHFRYHULQJ DQG µUHWXUQLQJ¶ WR WKH VXVFHSWLEOH
population. The remaining (persistent) cases present in primary care.  
(4) Children who are referred to specialist care undergo formal assessment and diagnosis.  
 3DWLHQWV IRU ZKRP D GLDJQRVLV RI 20( LV FRQILUPHG DIWHU WKUHH PRQWKV µZDWFKIXO ZDLWLQJ¶ KDYH D
capacity to benefit from VTs for OME and should be considered for surgical intervention according to 
NICE guidance. 
Legend:  
Boxes represent mutually exclusive, collectively exhaustive states in which parts of the population of 
children find themselves. 
Arrows represent the transition probabilities (incidence and recovery rates) and the waiting time that link the 
states. 
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Figure 2. Monte Carlo simulation of expected annual incidence of bilateral OME 
with a hearing level of +25 dB in England (reference year 2010, age groups 2 to 8 
years) 
 
Legend:  
x-axis: expected annual incidence of bilateral OME with +25 dBHL in England (2010). 
y-axis: frequency of observing a particular output value based on 10,000 iterations of the simulation model. 
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Figure 3. Expected number of children with capacity to benefit from VTs for OME 
depending on total waiting time in England (reference year 2010, age groups 2 to 8 
years)* 
 
*Given different starting estimates of the total annual incidence of bilateral OME with hearing level of 
+25dB for the age groups 2 to 8 from the Monte Carlo simulation (Figure 2) of approximately 102,083 cases 
(mean estimate); 63,800 cases (lower 5% bound); and 143,600 cases (upper 95% bound). 
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Appendix A. Systematic literature review: Search strategy and data extraction 
A systematic literature review was carried out using the databases PubMed, DARE, Scopus, Web of Science 
and the Cochrane Library (timespan: all available years; restriction to studies in English language). After 
removing duplicates, 1302 studies were screened independently by the first and second authors based on pre-
defined criteria. To be eligible, studies needed to (i) be population-based screening studies; (ii) have a 
prospective design; (iii) follow defined case finding and diagnostic methods; (iv) provide incidence rates by 
year of age; and (v) be conducted in Europe or North America. The detailed rationale for each criterion is 
stated in Appendix B. Study selection was discussed among members of the research team, with the Project 
Steering Group and during a workshop with UK-based clinical and epidemiological experts. Those studies 
judged to be in line with the selection criteria were retained.  
Database Search criteria Number 
of results 
DARE 
(("otitis media with effusion" OR "glue ear" OR "non suppurative otitis media" OR 
"serous otitis media" OR "secretory otitis media" OR "middle ear effusion" OR 
"purulent otitis media with effusion")) AND (("prevalence" OR "incidence" OR 
"epidemiology" OR "occurrence")) AND (("child*" OR "kid*" OR "infan*")) 
15 
Cochrane 
library 
( "otitisQUOTESPACEmediaQUOTESPACEwithQUOTESPACEeffusion" OR 
"glueQUOTESPACEear" OR 
"nonQUOTESPACEsuppurativeQUOTESPACEotitisQUOTESPACEmedia" OR 
"serousQUOTESPACEotitisQUOTESPACEmedia" OR 
"secretoryQUOTESPACEotitisQUOTESPACEmedia" OR 
"middleQUOTESPACEearQUOTESPACEeffusion" OR 
"purulentQUOTESPACEotitisQUOTESPACEmediaQUOTESPACEwithQUOTESPA
CEeffusion" ) and ( "prevalence" OR "incidence" OR "epidemiology" OR "occurrence" 
) and ( "child*" OR "kid*" OR "infan*" ) not ( 
"acuteQUOTESPACEotitisQUOTESPACEmedia" OR 
"recurrentQUOTESPACEacuteQUOTESPACEotitisQUOTESPACEmedia" ) not ( 
"adult*" ) NOT ( "animal*" ) NOT ( "cleftQUOTESPACEpalate" OR 
"down'sQUOTESPACEsyndrome" OR "downQUOTESPACEsyndrome" ) in Cochrane 
Database of Systematic Reviews" 
57 
Web of 
science 
 
Topic=(("otitis media with effusion" OR "glue ear" OR "non suppurative otitis media" 
OR "serous otitis media" OR "secretory otitis media" OR "middle ear effusion" OR 
"purulent otitis media with effusion")) AND Topic=("prevalence" OR "incidence" OR 
"epidemiology" OR "occurrence") AND Topic=(("child*" OR "kid*" OR "infan*")) 
1277RSLF DFXWHRWLWLVPHGLD25UHFXUUHQWDFXWHRWLWLVPHGLD´127
Topic=("adult*")NOT Topic=("animal*")NOT Topic=(("cleft palate" OR "down's 
syndrome" OR "down syndrome")) Refined by: Languages=( ENGLISH ) AND 
[excluding] Subject Areas=( PHYSICS OR URBAN STUDIES OR PLANT 
SCIENCES OR HISTORY ) Timespan=All Years. Lemmatization=On    
635 
PubMed 
(((((("otitis media with effusion"[All Fields] OR "glue ear"[All Fields] OR "non 
suppurative otitis media"[All Fields] OR "serous otitis media"[All Fields] OR 
"secretory otitis media"[All Fields] OR "middle ear effusion"[All Fields] OR (("otitis 
media, suppurative"[MeSH Terms] OR ("otitis"[All Fields] AND "media"[All Fields] 
AND "suppurative"[All Fields]) OR "suppurative otitis media"[All Fields] OR 
538 
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("purulent"[All Fields] AND "otitis"[All Fields] AND "media"[All Fields]) OR 
"purulent otitis media"[All Fields]) AND effusion[All Fields])) AND ("prevalence"[All 
Fields] OR "incidence"[All Fields] OR "epidemiology"[All Fields] OR 
"occurrence"[All Fields])) AND ("child*"[All Fields] OR "kid*"[All Fields] OR 
"infan*"[All Fields])) NOT ("acute otitis media"[All Fields] OR "recurrent acute otitis 
media"[All Fields])) NOT "adult*"[All Fields]) NOT "animal*"[All Fields]) NOT 
("cleft palate"[All Fields] OR "down's syndrome"[All Fields] OR "down syndrome"[All 
Fields]) AND ("humans"[MeSH Terms] AND English[lang]) 
Scopus 
(ALL(("otitis media with effusion" OR "glue ear" OR "non suppurative otitis media" 
OR "serous otitis media" OR "secretory otitis media" OR "middle ear effusion" OR 
"purulent otitis media with effusion")) AND ALL(("prevalence" OR "incidence" OR 
"epidemiology" OR "occurrence")) AND ALL(("child*" OR "kid*" OR "infan*")) 
AND NOT ALL(("acute otitis media" OR "recurrent acute otitis media")) AND NOT 
ALL(("adult*")) AND NOT ALL(("animal*")) AND NOT ALL(("cleft palate" OR 
"down's syndrome" OR "down syndrome"))) AND (LIMIT-TO(LANGUAGE, 
"English")) AND (EXCLUDE(SUBJAREA, "AGRI") OR EXCLUDE(SUBJAREA, 
"PHYS")) 
947 
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Appendix B. Study inclusion criteria   
Inclusion criteria Rationale Exclusion criteria 
Population-based 
screening study 
For valid estimates of incidence, the denominator 
should include all, or a representative sample of, 
individuals at risk.  
As regards hearing loss: most literature focuses on 
clinical populations. Thus, current hearing loss data is 
from a community-based study focused on bilateral 
middle ear effusion1 (p.44).  
1) Utilisation-based studies (i.e. with clinical populations actually visiting the doctor as 
denominator). Single hospital or practice cannot usually be assumed to provide care for a 
well-defined population that is representative of a larger group.2 
2) Trial-based studies. Results may be difficult to generalise to a general population 
setting, if particular groups are over- or underrepresented. 
3) Studies with high-risk populations (e.g. pre-term babies on intensive care units, 
exclusive focus on children in daycare). 
4) Clinical specialist populations (for estimating the proportion of hearing loss among all 
OME cases). If the denominator are children who have already been referred to ENT,3-5 
this may either lead to overestimation (due to selectivity of more severe cases) or 
underestimation (due to bias in detection and presentation among parents and/ or gaps in 
referral from primary care). 
5) Self-report studies. As regards incidence and hearing loss, parents have been shown to 
be inaccurate in their judgments regarding the presence of hearing loss that may 
accompany an episode of OME.6 
Prospective design OME often presents asymptomatically, which 
complicates retrospective diagnosis of OME. 
 
Retrospective designs (e.g. parent interviews or analysis of doctor consultations). These 
will substantially underestimate the true incidence of OME 7 and are thus not a reliable 
case finding design for OME. 
Case finding 
methods and 
diagnosis 
The recommended diagnostic algorithm for OME 
combines impedance audiometry (tympanometry) with 
pneumatic otoscopy.8 
OME is diagnosed when tympanometry reveals a flat 
curve (relative gradient less than 0.1, type B) or middle 
ear pressure between -399 to -200 daPa (C2 curve), 
when the tympanic membrane has no or reduced 
mobility, or fluid or air bubbles are evident behind the 
ear drum.9 
Studies that do not provide correspondingly defined case finding and diagnostic methods. 
Stratified by year of 
age  
Incidence of OME is known to vary considerably by 
age.10 
Aggregate (e.g. five-year) rates. This is likely to obscure key differences in incidence 
across age groups. 
Studies conducted in 
Europe or North 
America 
Incidence of OME may be influenced by climatic 
settings.11 
Studies conducted in different climatic settings than England. 
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Appendix C. Estimation of susceptible population 
For valid estimations of incident cases, children with prevalent OME at the beginning of the study period 
need to be subtracted from the total population to obtain an estimate of the susceptible population (i.e. the 
population at risk). This is because the denominator of the cumulative incidence is defined as the number of 
children at risk at beginning of the study period rather than the total population.12 Point prevalences are taken 
from population-based studies. The estimates are lower than those reported in a review by Zielhuis et al,10 
which may be due to the amalgamation of point and period prevalences (time frames over which prevalence 
has been measured are not reported). 
 
j 
Age group 
Pj 
Point prevalence (%) 
 
Reference 
Nj 
Total population 
Sj = Nj-( Nj*Pj) 
Susceptible population 
2 10.61 13        667,185                   596,423  
3 9.8 2        640,232                   577,489  
4 8.8 2        620,326                   565,737  
5 10 2        606,770                   546,093  
6 6.1 2        598,725                   562,203  
7 3.04 13        577,767                   560,183  
8 1.11 13         560,460                   554,233  
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